Picture loading failed.

Anti-CD40 therapeutic antibody (Pre-made Iscalimab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

CFZ533 (ISCALIMAB) is a fully human antibody that blocks CD40, a co-stimulatory protein involved in the activation of immune B-cells, which are crucial to the development of Sjogren's syndrome. It is currently in Phase II of clinical trial for Sjogren's Syndrome.

Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-280-1mg 1mg 3090
GMP-Bios-ab-280-10mg 10mg 21890
GMP-Bios-ab-280-100mg 100mg 148000
GMP-Bios-ab-280-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD40 therapeutic antibody (Pre-made Iscalimab biosimilar,Whole mAb)
INN Name Iscalimab
TargetCD40
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2017
Year Recommended2018
CompaniesNovartis;XOMA
Conditions Approvedna
Conditions ActiveGraves' disease;Lupus nephritis;Myasthenia gravis;Renal transplant rejection;Sjogren's syndrome;Systemic lupus erythematosus
Conditions DiscontinuedRheumatoid arthritis
Development Techna